Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Baxter International Inc(BAX)
Today’s top pick 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BAX
11/11/2026: BAX (3-star) is a STRONG-BUY. BUY for 2 days. Simulated Profits (-0.30%). Updated daily EoD!
Baxter International Inc is a globally recognized provider of essential medical devices and clinical therapies, specializing in dialysis, infusion systems, and surgical tools. The company’s primary strength lies in its deep integration into hospital workflows and a strong leadership position in home peritoneal dialysis. Its current investment story centers on operational streamlining and a planned spin-off of the Kidney Care business to unlock shareholder value. Investors must monitor risks related to its significant debt load, integration hurdles from past acquisitions, and constant pricing pressure in the medtech sector. The stock may appeal to income-oriented investors seeking a stable, long-standing healthcare player with a clear restructuring roadmap.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth is moderate and currently relies more on operational restructuring than rapid innovation-led expansion. |
| Momentum investor | Weak fit | The stock has not demonstrated the sustained upward price momentum typically required for a momentum strategy. |
| Value investor | Mixed fit | Valuation may be attractive relative to historical averages, but requires confidence in the company's turnaround plan. |
| Dividend investor | Strong fit | Baxter provides a stable, consistent dividend, making it suitable for income-oriented portfolios. |
| Low-risk investor | Mixed fit | While healthcare is a defensive sector, the company's current leverage and operational challenges introduce moderate risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock can experience swings based on management updates and healthcare spending outlooks. |
| Valuation risk | Medium | Market sentiment toward turnaround stories can lead to compression of valuation multiples. |
| Competition risk (Medtech peers) | Medium / high | Intense rivalry in dialysis and infusion markets forces constant innovation and pricing pressure. |
| Business quality | Strong | Baxter holds durable, essential market positions in critical hospital infrastructure products. |
| Dividend income | Medium | Dividends are reliable but capital allocation is currently pressured by debt repayment needs. |
| Execution risk | High | Successful integration of recent acquisitions and the planned Kidney Care spin-off are critical to future performance. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 21.7% | Avg. Invested days 40 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/11/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Sector & Industry Intelligence
Sector snapshot as of 2026-11-10
Sector
Healthcare
- Signal
- Constructive
- Sentiment
- Strong Bullish
- Market state
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 60.0%
- Active BUY / eligible
- 69 / 115
- 22-session BUY-count change
- +29
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Medical Instruments & Supplies
- BUY participation
- 50.0%
- Active BUY / eligible
- 3 / 6
- 22-session BUY-count change
- 0
The sector signal does not change this stock’s BUY, SELL, or PASS advisory.
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.67B USD | Price to earnings Ratio - | 1Y Target Price 27.25 |
Price to earnings Ratio - | 1Y Target Price 27.25 | ||
Volume (30-day avg) 6.9M shares | Beta 0.67 | 52 Weeks Range 15.72 - 29.99 | Updated Date 11/11/2026 |
52 Weeks Range 15.72 - 29.99 | Updated Date 11/11/2026 | ||
Dividends yield (FY) 0.15% | Basic EPS (TTM) -1.21 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Medical Products & Therapies | Infusion pumps, IV solutions, and nutritional products. | The company sells essential, high-volume products to hospitals globally. |
| Kidney Care | Dialysis equipment and services for home and clinic patients. | A stable business segment with steady demand from patients with chronic kidney disease. |
| Advanced Surgery | Hemostats and sealants used in operating rooms. | Specialized surgical products that command strong market positions. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When Before Market | Estimate 0.51 | Actual 0.58 |
Profitability
Profit Margin -6.23% | Operating Margin (TTM) 9.88% |
Management Effectiveness
Return on Assets (TTM) 2.71% | Return on Equity (TTM) -9.04% |
Valuation
Trailing PE - | Forward PE 12.48 | Enterprise Value 20.50B | Price to Sales(TTM) 1.18 |
Enterprise Value 20.50B | Price to Sales(TTM) 1.18 | ||
Enterprise Value to Revenue 1.77 | Enterprise Value to EBITDA 19.23 | Shares Outstanding 517.35M | Shares Floating 514.76M |
Shares Outstanding 517.35M | Shares Floating 514.76M | ||
Percent Insiders 0.34 | Percent Institutions 109.13 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.